Authors
Xiaojia Wang, MD, is an oncologist in the Department of Breast Medical Oncology at the Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital and a key researcher at the Institute of Cancer and Basic Medicine (IBMC) at the Chinese Academy of Sciences in Hangzhou, China.
Advertisement
Advertisement
Trending on OncLive
1
EU, Japanese Approval Is Sought for Savolitinib Plus Osimertinib in MET-Driven EGFR-Mutated NSCLC
2
Dr Hansen on the Potential Role of GPRC5D-Targeted CAR T-Cell Therapy in Myeloma
3
Belzutifan Plus Lenvatinib Raises New Sequencing Questions in Advanced RCC
4
Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast Cancer
5
